Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas.
Silvana NovelliAnna MonterM Pilar García-MuretRodrigo MartinoJavier BrionesJorge SierraPublished in: International journal of hematology (2019)
Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- free survival
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- multiple sclerosis
- low dose
- oxidative stress
- patient reported outcomes
- mesenchymal stem cells
- rectal cancer
- smoking cessation
- disease activity
- hematopoietic stem cell